Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Peripheral blood CD4posCD25posFoxP3pos cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig

Fig. 2

A–C Modulation of peripheral blood cytokines and T-lymphocyte subpopulations by CTLA4-Ig treatment in RA. A IL-6, TGF-b, and IL-10 serum levels of RA patients at study entry and after 6 and 12 months of follow-up of CTLA4-Ig treatment in RA patients (whole cohort, cohort 1, and cohort 2, respectively) and healthy controls. B Peripheral blood CD4posCD25posFoxP3pos, CD4posCD25posCD127neg, and CD4posIL17pos cell percentage at study entry and after 6 and 12 months of follow-up of CTLA4-Ig treatment in RA patients (whole cohort, cohort 1, and cohort 2 respectively) and healthy controls. C STAT3 and STAT5 gene expression in CD4pos cells from peripheral blood of RA patients at study entry and after 6 and 12 months of follow-up of CTLA4-Ig treatment (whole cohort, cohort 1, and cohort 2, respectively) and healthy controls. All comparisons between groups were done using the Mann–Whitney U test while all comparisons between different time points within the same cohort were done using the Wilcoxon matched-pairs signed rank test. IL, interleukin; TGFβ, transforming growth factor beta; CD, cluster designation; RA, rheumatoid arthritis

Back to article page